In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Simulations Plus (SLP – Research Report). The company’s shares closed yesterday at $40.79.
According to TipRanks, Hewitt is an analyst with an average return of -3.8% and a 35.65% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Repligen, and HealthStream.
Simulations Plus has an analyst consensus of Moderate Buy, with a price target consensus of $55.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $52.69 and a one-year low of $32.44. Currently, Simulations Plus has an average volume of 82.6K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SLP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Simulations Plus (SLP) Company Description:
Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.
Read More on SLP:
